oral glp-1 agonist The challenge of developing alternatives to Ozempic, Wegovy and Mounjaro GLP-1 Agonists - What is
Description
Lancet Diabetes endocrinol (2019) 7(10):77685

Nat Med

2007;292:R1092R1100

JAMA (2022) 327:138

Theoretical interaction risk is lower, but "lower" does not mean "zero." No clinical data exists for any of these combinations with retatrutide

However, endogenous GLP-1 can be inactivated by dipeptidyl peptidase-4 (DPP-4) [4]
